PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
One step forward, two steps back for biotech.
Another SERD catalyst and the son of Darzalex take centre stage.
Tough equity markets as well as competitor developments prompt a narrowed focus.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
